Issues related to insulin pricing.
Issues related to Medicare Part D.
Issues regarding vaccines.
Issues related to the orphan drug tax credit.
Duration: January 1, 2019
to
present
General Issues: Medicare/Medicaid , Taxation/Internal Revenue Code , Health Issues , Trade (Domestic & Foreign)
Spending: about $840,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2019: U.S. Senate, House of Representatives
Related Foreign Entities:
Sanofi SA (Paris, FRA); contribution to lobbying: $0; ownership 100%
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Beau Schuyler
LD- Cong. Tanner, LD - Cong. McIntyre
LD - Cong. Tanner, LD - Cong, McIntyre
Legislative Director: Rep. Tanner; Legislative Director: Rep. McIntyre
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Thorn Run Partners lobbied for Sanofi US Services Inc. , earning $40,000. The report was filed on April 22.
Original Filing: 301575363.xml
Lobbying Issues
Issues related to insulin pricing.
Issues related to Medicare Part D.
Issues regarding vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the orphan drug tax credit.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2023
In Q4, Thorn Run Partners lobbied for Sanofi US Services Inc. , earning $40,000. The report was filed on Jan. 22.
Original Filing: 301540598.xml
Lobbying Issues
Issues related to insulin pricing.
Issues related to Medicare Part D.
Issues regarding vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the orphan drug tax credit.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2023
In Q3, Thorn Run Partners lobbied for Sanofi US Services Inc. , earning $40,000. The report was filed on Oct. 20, 2023.
Original Filing: 301509580.xml
Lobbying Issues
Issues related to insulin pricing.
Issues related to Medicare Part D.
Issues regarding vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the orphan drug tax credit.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2023
In Q2, Thorn Run Partners lobbied for Sanofi US Services Inc. , earning $40,000. The report was filed on July 20, 2023.
Original Filing: 301485093.xml
Lobbying Issues
Issues related to insulin pricing.
Issues related to Medicare Part D.
Issues regarding vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the orphan drug tax credit.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2023
In Q1, Thorn Run Partners lobbied for Sanofi US Services Inc. , earning $40,000. The report was filed on April 20, 2023.
Original Filing: 301463812.xml
Lobbying Issues
Issues related to insulin pricing.
Issues related to Medicare Part D.
Issues regarding vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the orphan drug tax credit.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2022
In Q4, Thorn Run Partners lobbied for Sanofi US Services Inc. , earning $40,000. The report was filed on Jan. 20, 2023.
Original Filing: 301436313.xml
Lobbying Issues
Issues related to insulin pricing.
Issues related to Medicare Part D.
Issues regarding vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the orphan drug tax credit.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2022
In Q3, Thorn Run Partners lobbied for Sanofi US Services Inc. , earning $40,000. The report was filed on Oct. 21, 2022.
Original Filing: 301420318.xml
Lobbying Issues
Issues related to insulin pricing.
Issues related to Medicare Part D.
Issues regarding vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the orphan drug tax credit.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2022
In Q2, Thorn Run Partners lobbied for Sanofi US Services Inc. , earning $40,000. The report was filed on July 20, 2022.
Original Filing: 301393316.xml
Lobbying Issues
Issues related to insulin pricing. Issues related to Medicare Part D. Issues regarding vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the orphan drug tax credit.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2022
In Q1, Thorn Run Partners lobbied for Sanofi US Services Inc. , earning $40,000. The report was filed on April 20, 2022.
Original Filing: 301369276.xml
Lobbying Issues
Issues related to insulin pricing. Issues related to Medicare Part D. Issues regarding vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to respiratory syncytial virus.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to the orphan drug tax credit.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2021
In Q4, Thorn Run Partners lobbied for Sanofi US Services Inc. , earning $40,000. The report was filed on Jan. 19, 2022.
Original Filing: 301328554.xml
Lobbying Issues
Issues related to insulin pricing. Issues related to Medicare Part D. Issues regarding vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to respiratory syncytial virus.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to the orphan drug tax credit.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2021
In Q3, Thorn Run Partners lobbied for Sanofi US Services Inc. , earning $40,000. The report was filed on Oct. 20, 2021.
Original Filing: 301314664.xml
Lobbying Issues
Issues related to insulin pricing. Issues related to Medicare Part D. Issues regarding vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to respiratory syncytial virus.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to the orphan drug tax credit.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2021
In Q2, Thorn Run Partners lobbied for Sanofi US Services Inc. , earning $40,000. The report was filed on July 20, 2021.
Original Filing: 301289302.xml
Lobbying Issues
Issues related to insulin pricing. Issues related to Medicare Part D. Issues regarding vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to respiratory syncytial virus.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues affecting pharmaceuticals in health care and taxation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2021
In Q1, Thorn Run Partners lobbied for Sanofi US Services Inc. , earning $40,000. The report was filed on April 20, 2021.
Original Filing: 301262373.xml
Lobbying Issues
Issues related to insulin pricing. Issues related to Medicare Part D. Issues regarding vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues regarding drug pricing. Issues regarding respiratory syncytial virus (RSV) prevention.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues affecting pharmaceuticals in health care and taxation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2020
In Q4, Thorn Run Partners lobbied for Sanofi US Services Inc. , earning $40,000. The report was filed on Jan. 20, 2021.
Original Filing: 301241396.xml
Lobbying Issues
Issues related to insulin pricing. Issues related to Medicare Part D. Issues regarding vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues regarding the extension of the pediatric priority review voucher program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues affecting pharmaceuticals in health care and taxation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2020
In Q3, Thorn Run Partners lobbied for Sanofi US Services Inc. , earning $40,000. The report was filed on Oct. 20, 2020.
Original Filing: 301220806.xml
Lobbying Issues
Issues related to insulin pricing. Issues related to Medicare Part D. Issues regarding vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Patient Protection and Affordable Care Enhancement Act (H.R. 1425).
Issues regarding the extension of the pediatric priority review voucher program.
Issues regarding respiratory syncytial virus (RSV).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues affecting pharmaceuticals in health care and taxation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2020
In Q2, Thorn Run Partners lobbied for Sanofi US Services Inc. , earning $40,000. The report was filed on July 20, 2020.
Original Filing: 301196532.xml
Lobbying Issues
Issues related to insulin pricing. Issues related to Medicare Part D. Issues regarding vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Patient Protection and Affordable Care Enhancement Act (H.R. 1425).
Issues regarding respiratory syncytial virus (RSV).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues affecting pharmaceuticals in health care and taxation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2020
In Q1, Thorn Run Partners lobbied for Sanofi US Services Inc. , earning $40,000. The report was filed on April 20, 2020.
Original Filing: 301176213.xml
Lobbying Issues
Issues related to insulin pricing. Issues related to Medicare Part D. Issues regarding vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to insulin.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act.
Issues regarding respiratory syncytial virus (RSV).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues affecting pharmaceuticals in health care and taxation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2019
In Q4, Thorn Run Partners lobbied for Sanofi US Services Inc. , earning $40,000. The report was filed on Jan. 21, 2020.
Original Filing: 301128809.xml
Lobbying Issues
Issues related to insulin pricing. Issues related to Medicare Part D. Issues regarding vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to insulin.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues affecting pharmaceuticals in health care and taxation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to biologics and USMCA.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2019
In Q3, Thorn Run Partners lobbied for Sanofi US Services Inc. , earning $40,000. The report was filed on Oct. 16, 2019.
Original Filing: 301066368.xml
Lobbying Issues
Issues related to insulin pricing. Issues related to Medicare Part D. Issues regarding vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to insulin.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues affecting pharmaceuticals in health care and taxation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to biologics and USMCA.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2019
In Q2, Thorn Run Partners lobbied for Sanofi US Services Inc. , earning $40,000. The report was filed on July 18, 2019.
Original Filing: 301048529.xml
Lobbying Issues
Issues related to insulin pricing. Issues related to Medicare Part D.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to insulin.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues affecting pharmaceuticals in health care and taxation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2019
In Q1, Thorn Run Partners lobbied for Sanofi US Services Inc. , earning $40,000. The report was filed on April 16, 2019.
Original Filing: 301026535.xml
Lobbying Issues
Issues related to insulin pricing.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to insulin.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues affecting pharmaceuticals in health care and taxation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2019
Thorn Run Partners filed a lobbying registration on Feb. 13, 2019 to represent Sanofi US Services Inc., effective Jan. 1, 2019.
Original Filing: 301020293.xml
Issue(s) they said they’d lobby about: Issues affecting pharmaceuticals in health care and taxation. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate